Treffer: [Multicenter retrospective study of transoral robotic surgery for supraglottic laryngeal cancer].

Title:
[Multicenter retrospective study of transoral robotic surgery for supraglottic laryngeal cancer].
Authors:
Xu K; Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan 430030, China., Tao L; Department of Otolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China., Wang Y; Department of Otorhinolarygology, The First Affiliated Hospital of China Medical University, Shenyang 110001, China., Liang FY; Department of Otorhinolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Key Laboratory of Epigenetics and Gene Regulation of Malignant Tumor in Guangdong Province, Guangzhou 510280, China., Xu CZ; Department of Otolaryngology Head and Neck Surgery, Eye & ENT Hospital, Fudan University, Shanghai 200031, China., Deng LL; Department of Otorhinolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Key Laboratory of Epigenetics and Gene Regulation of Malignant Tumor in Guangdong Province, Guangzhou 510280, China., Zou X; Department of Otorhinolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Key Laboratory of Epigenetics and Gene Regulation of Malignant Tumor in Guangdong Province, Guangzhou 510280, China., Lu X; Department of Otorhinolaryngology Head and Neck Surgery, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan 430030, China., Huang XM; Department of Otorhinolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Key Laboratory of Epigenetics and Gene Regulation of Malignant Tumor in Guangdong Province, Guangzhou 510280, China., Han P; Department of Otorhinolaryngology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Key Laboratory of Epigenetics and Gene Regulation of Malignant Tumor in Guangdong Province, Guangzhou 510280, China.
Source:
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery [Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi] 2025 Mar 07; Vol. 60 (3), pp. 266-271.
Publication Type:
Journal Article; Multicenter Study; English Abstract
Language:
Chinese
Journal Info:
Publisher: Zhonghua yi xue hui za zhi she Country of Publication: China NLM ID: 101247574 Publication Model: Print Cited Medium: Print ISSN: 1673-0860 (Print) Linking ISSN: 16730860 NLM ISO Abbreviation: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi Subsets: MEDLINE
Imprint Name(s):
Original Publication: Beijing : Zhonghua yi xue hui za zhi she, 2005-
MeSH Terms:
Robotic Surgical Procedures*/methods , Laryngeal Neoplasms*/surgery, Humans ; Retrospective Studies ; Male ; Female ; Aged ; Carcinoma, Squamous Cell/surgery ; Operative Time ; Middle Aged ; Length of Stay ; Laryngectomy/methods
Grant Information:
2023P-ZD13 Guangzhou Health Science and Technology Project
Contributed Indexing:
Local Abstract: [Publisher, Chinese] 目的： 初步探讨经口机器人手术（TORS）治疗声门上型喉癌的安全有效性及近期疗效。 方法： 回顾性分析2018年1月至2024年4月中山大学孙逸仙纪念医院、华中科技大学同济医学院附属同济医院、复旦大学附属眼耳鼻喉科医院及中国医科大学附属第一医院采用TORS治疗声门上型喉癌的患者资料，分析手术时间、术中出血量、术后住院天数、围手术期气管切开情况、鼻饲饮食、并发症及近期随访情况。使用Python进行统计学分析。 结果： 4个中心共纳入27例声门上型喉癌患者，其中男性24例，女性3例，年龄66（65，68）岁［ M （ Q1 ， Q3 ），下同］。包括鳞状细胞癌26例，腺样囊性癌1例；T1期10例（37.04%），T2期13例（48.15%），T3期4例（14.81%）；N0期14例（51.85%），N1期7例（25.93%），N2期6例（22.22%）。采用达芬奇Si 23例，达芬奇Xi 4例，机器人手术时间为53（30，58）min，同期行颈淋巴清扫25例，术前新辅助治疗8例（29.63%），术后放疗13例（48.15%）。气管切开11例（40.74%），留置胃管23例（85.19%），留置胃管时间为16（12，21）d，术后住院时长为（9.19±4.07）d；随访时间12（3，30）个月。2例出现局部复发，3年生存率为100%，3年无病生存率为94.1%。 结论： 在适应证选择合理的前提下，应用TORS治疗声门上型喉癌近期疗效满意，具有安全、有效、微创的优点，可作为治疗新选择。.
Entry Date(s):
Date Created: 20250320 Date Completed: 20250403 Latest Revision: 20250529
Update Code:
20250530
DOI:
10.3760/cma.j.cn115330-20240807-00466
PMID:
40113567
Database:
MEDLINE

Weitere Informationen

Objective: To explore the safety, effectiveness, and short-term outcomes of transoral robotic surgery (TORS) for supraglottic laryngeal cancer. Methods: A retrospective analysis was conducted on patients with supraglottic laryngeal cancer who underwent TORS at Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Eye Ear Nose and Throat Hospital of Fudan University, and the First Affiliated Hospital of China Medical University between January 2018 and April 2024. Data on operative time, intraoperative blood loss, postoperative hospital stay, perioperative tracheostomy, nasogastric feeding, complications, and short-term follow-up were analyzed. Statistical analysis was performed using Python. Results: A total of 27 patients with supraglottic laryngeal cancer were included from the four centers, including 24 males and 3 females, with a median age of 66 (65, 68) years [ M ( Q<subscript>1</subscript> , Q<subscript>3</subscript> ), same below]. There were 26 cases of squamous cell carcinoma and 1 case of adenoid cystic carcinoma.The TNM staging included T1 in 10 cases (37.04%), T2 in 13 cases (48.15%), and T3 in 4 cases (14.81%); N0 in 14 cases (51.85%), N1 in 7 cases (25.93%), and N2 in 6 cases (22.22%). The Da Vinci Si system was used in 23 cases, and the Da Vinci Xi in 4 cases. The robotic surgical time was 53 (30, 58) min. Concurrent neck dissection was performed in 25 cases, neoadjuvant therapy was given preoperatively in 8 cases (29.63%), and postoperative radiotherapy was administered in 13 cases (48.15%). Tracheostomy was performed in 11 cases (40.74%). Nasogastric tube placement was required in 23 cases (85.19%), with a median duration of 16 (12, 21) days. The postoperative hospital stay was 9.19±4.07 days. The median follow-up time was 12 (3, 30) months. Local recurrence occurred in 2 cases. The 3-year overall survival rate was 100%, and the 3-year disease-free survival rate was 94.1%. Conclusion: With appropriate patient selection, TORS for supraglottic laryngeal cancer demonstrates satisfactory short-term outcomes, thereby offering advantages in safety, efficacy, and minimal invasiveness, which can be considered a new treatment option for this condition.